Rahul Anand Devathu

All Publications

• Artificial Intelligence in Atrial Fibrillation - Timely Diagnosis, Risk Assessment and Personalized Management. Indian pacing and electrophysiology journal Chatterjee, K., Verma, A., Godinez, E., Gonzalez, D. J., Devathu, R., Alhusseini, M. I., Fazal, M., Baykaner, T. 2026

  Abstract

  Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide and is associated with substantial morbidity and mortality, including stroke, systemic embolism, heart failure, and dementia. Timely diagnosis, accurate risk stratification, and personalized management are necessary to improving outcomes. Recent advancements in artificial intelligence (AI) have expanded the potential for AF care, leveraging machine and deep learning approaches for enhanced detection, risk assessment, and therapeutic guidance. In this review, we summarize the clinical integration of AI into AF management across three domains. First, AI-enhanced electrocardiography (ECG) and wearable photoplethysmography devices allow early detection and long-term, non-invasive screening of AF, including identification of subclinical or paroxysmal AF from routine sinus rhythm recordings. Second, AI models have the potential to refine stroke risk stratification and personalize anticoagulation decision-making by integrating multidimensional clinical data, providing individualized risk assessments beyond traditional scoring systems like CHA2DS2-VASc. Finally, AI has been increasingly integrated into procedural planning and execution for AF ablation, helping to identify optimal ablation targets and predict post-procedural arrhythmia recurrence risk for a given rhythm control strategy, based on imaging and biosignal-derived features. In summary, the emerging integration of machine learning approaches into AF management highlights its transformative potential to offer earlier detection, more precise and personalized risk stratification, and tailored therapeutic strategies and patient follow up. Despite these advancements, the clinical implementation of AI in AF management remains primitive, requiring large-scale validation, supplemental clinical oversight, and regulatory guidance to ensure safe and effective integration into our daily practices.

  View details for DOI 10.1016/j.ipej.2026.01.011

  View details for PubMedID 41611206

• Artificial Intelligence-driven Detection, Mapping, and Personalized Therapy for Atrial Fibrillation. The Journal of innovations in cardiac rhythm management Gonzalez, D. J., Kambampati, S., Godinez, E., Paranjpe, I., Chatterjee, K., Devathu, R., Verma, A., Sun, E., Ma, C., Fazal, M., Baykaner, T. 2026; 17 (1): 6578-6590

  Abstract

  Atrial fibrillation (AF), the most common arrhythmia worldwide, affects approximately 59 million people globally. It poses a significant health burden by increasing morbidity and mortality. Artificial intelligence (AI) is emerging as a potentially transformative technology across the AF care continuum. This review synthesizes current evidence and critically evaluates AI applications in AF management, including innovations in detection and screening using electrocardiography and wearables; advanced mapping techniques using signal processing and computational modeling to guide catheter ablation; machine learning-based prediction of treatment outcomes; and personalization of long-term therapy, such as anticoagulation. Key studies and trials illustrating AI's capabilities in improving diagnostic yield, refining ablation targets, and enhancing prognostic accuracy are analyzed. The potential for AI to facilitate integrated care pathways, such as the "AF Better Care" approach, is considered, balancing innovation against clinical practicality, rigorous validation, and workflow integration. While AI shows considerable potential to augment precision in AF management, significant challenges concerning data generalizability, model interpretability, clinical utility validation, and equitable implementation remain. Optimal integration requires careful alignment with clinical expertise and a focus on patient-centric outcomes. Addressing these challenges through collaborative efforts among clinicians, researchers, and technology developers will be essential to fully realize AI's promise in improving AF care. Future research should prioritize robust validation, transparent methodologies, and practical implementation strategies to ensure that AI effectively enhances patient outcomes.

  View details for DOI 10.19102/icrm.2026.17011

  View details for PubMedID 41657709

  View details for PubMedCentralID PMC12880197

• Treatment Options, Regulatory Pathways and Global Patterns of Use for Cardiac Implantable Devices in Patients With Titanium Allergy. Journal of cardiovascular electrophysiology Devathu, R., Chatterjee, K., Godinez, E., Kambampati, S., Gonzalez, D. J., Kim, M. H., Li, J., Paranjpe, I., Fazal, M., Brucker, R., Baykaner, T. 2025

  Abstract

  Titanium hypersensitivity is an uncommon but important challenge in patients requiring cardiac implantable electronic devices (CIEDs). Reactions are difficult to predict, often mimic infection, and complicate timely diagnosis.We reviewed diagnostic considerations, therapeutic strategies, regulatory pathways, and global distribution of coated devices. Data sources included prior case reports, regulatory guidelines, and industry distribution records.Management options range from conservative observation to prophylactic implantation of hypoallergenic devices. Gold-coated and polymer-coated alternatives are effective but constrained by production costs, lack of reimbursement, and limited availability. In the United States, access is possible through custom device and compassionate use pathways, both requiring extensive regulatory approvals. Globally, most requests originate from the U.S. and Europe, with fewer from other regions due to economic and cultural barriers.Improved awareness, streamlined regulatory frameworks, and multidisciplinary collaboration are essential to expand access and optimize outcomes for patients with titanium hypersensitivity.

  View details for DOI 10.1111/jce.70195

  View details for PubMedID 41286575

• Four devices, one solution: gold-coated cardiac resynchronization therapy with a defibrillator in a patient with titanium hypersensitivity. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing Devathu, R., Chatterjee, K., Godinez, E., Kambampati, S., Gonzalez, D. J., Kim, M. H., Verma, A., Wei, C., Fazal, M., Bowers, M., Baykaner, T. 2025

  Abstract

  Titanium hypersensitivity is a rare but important cause of recurrent complications in patients with cardiac implantable electronic devices (CIEDs). Despite titanium's biocompatibility, hypersensitivity reactions can mimic device infection, leading to repeated device removals before diagnosis.We report the management of a 67-year-old man with non-ischemic cardiomyopathy who presented to our institution after three failed cardiac resynchronization therapy with defibrillator (CRT-D) implantations over three years, each complicated by wound dehiscence and infection-like symptoms. The patient had been diagnosed with titanium hypersensitivity previously but prior attempts to mitigate exposure, including a Gore-Tex-wrapped device were unsuccessful. Therefore, a custom gold-plated CRT-D was obtained under U.S. Food and Drug Administration (FDA) compassionate use provisions. The gold-plated CRT-D was implanted via a right-sided approach. At one-year follow-up, the surgical site remained well-healed with no recurrent complications or device-related discomfort and left ventricular ejection fraction (LVEF) improved from 29% to 50%.This case underscores the diagnostic challenges of titanium allergy, the limitations of conventional management, and the value of multidisciplinary collaboration to navigate regulatory pathways and deliver durable, patient-specific solutions.

  View details for DOI 10.1007/s10840-025-02154-0

  View details for PubMedID 41148558